TRS33 Antibody

What is TRS33 and what cellular functions does it participate in?

TRS33 is a nonessential but conserved subunit of the TRAPP complex that plays crucial roles in membrane trafficking. Specifically, TRS33 contributes to the assembly of TRAPP II complex, which functions as a guanine nucleotide exchange factor (GEF) for certain Rab GTPases, including Ypt31/32 in yeast . The TRAPP complex is involved in tethering transport vesicles to the cis-Golgi membrane and regulating various aspects of membrane trafficking .

In yeast, while TRS33 itself is not essential for viability, it becomes essential in the absence of another TRAPP subunit, Trs65. This indicates functional redundancy between these subunits in TRAPP II assembly . Interestingly, unlike in yeast, TRS33 plays an essential role in Arabidopsis, where loss-of-function mutations affect apical meristematic growth and are lethal for apical growth .

How is TRS33 structurally and functionally related to other TRAPP subunits?

TRS33 shares sequence and localization similarities with Trs65, another TRAPP subunit. Both proteins localize predominantly to the trans-Golgi, co-localizing with the trans-Golgi marker Sec7 and to a lesser extent with the cis-Golgi marker Cop1 . Structurally, TRS33 interacts with several TRAPP I subunits, including Bet3, Bet5, and Trs31, while Trs65 interacts with Bet3, Trs31, and Trs23 .

How conserved is TRS33 across different species?

TRS33 is highly conserved from yeast to humans, though its functional importance varies across species. In yeast, TRS33 is nonessential but becomes essential in the absence of Trs65 . In contrast, Arabidopsis contains a single copy of the TRS33 gene (AtTRS33), and its loss-of-function is lethal for apical growth, indicating an essential role in plant development .

The human genome contains homologs of TRS33, with TRAPPC6A being one such related protein. TRAPPC6A is a component of the trafficking protein particle complex that tethers transport vesicles to the cis-Golgi membrane . The evolutionary conservation of TRS33 across diverse eukaryotes suggests its fundamental importance in cellular trafficking pathways, despite species-specific variations in its precise roles.

What criteria should be used to select an appropriate TRS33 antibody?

When selecting a TRS33 antibody, researchers should consider several critical factors:

• Target specificity: Verify that the antibody recognizes your specific TRS33 ortholog (yeast, plant, human, etc.) as sequences can vary across species.

• Immunogen information: Review the immunogen used to generate the antibody. Antibodies raised against recombinant full-length proteins or large domains may offer better recognition than those targeting short peptides .

• Validated applications: Confirm that the antibody has been validated for your intended applications (Western blot, immunofluorescence, immunoprecipitation, etc.) .

• Cross-reactivity profile: Check if the antibody cross-reacts with related TRAPP subunits, particularly Trs65 which shares sequence similarities with TRS33 .

• Lot-to-lot consistency: For critical experiments, it may be worth testing antibodies from different lots to ensure reproducible results.

A thorough review of the literature for papers that have successfully used TRS33 antibodies can provide valuable insights into antibody performance in specific experimental contexts.

What are the most reliable methods to validate TRS33 antibody specificity?

Validating TRS33 antibody specificity is essential for experimental reliability. Consider these methodological approaches:

• Knockout/knockdown controls: The gold standard for validation is using cells or tissues where TRS33 has been deleted or depleted. For yeast studies, use trs33Δ mutants as negative controls .

• Overexpression validation: Test the antibody in samples overexpressing tagged TRS33 to confirm the expected increase in signal.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to confirm that the specific signal disappears.

• Multiple antibody approach: Use antibodies raised against different epitopes of TRS33 and compare their staining patterns.

• Cross-species validation: If working with conserved regions, test the antibody across multiple species to verify conservation of the epitope.

• Molecular weight confirmation: Verify that the observed molecular weight matches the predicted size for TRS33 (approximately 18-24 kDa depending on the species) .

A comprehensive validation strategy using multiple approaches provides the highest confidence in antibody specificity and experimental results.

What controls are essential when using TRS33 antibodies in immunoprecipitation studies?

For immunoprecipitation (IP) experiments with TRS33 antibodies, include these essential controls:

• Isotype control: Perform parallel IPs with an isotype-matched irrelevant antibody to identify non-specific binding.

• Genetic knockout/knockdown: Include samples from TRS33-depleted cells to verify the specificity of bands in downstream analyses.

• Pre-immune serum: For polyclonal antibodies, use pre-immune serum as a negative control.

• Input control: Always run an input sample (typically 2-5% of IP material) to compare relative enrichment.

• Parallel IP of known interactors: Since TRS33 interacts with Bet3 and other TRAPP subunits, parallel IPs for these proteins can confirm the integrity of the complex .

• Reciprocal IP: If studying specific interactions (e.g., TRS33-Trs120), perform reciprocal IPs to validate the interaction .

Remember that TRS33 exists in a complex with other TRAPP subunits, so co-immunoprecipitation studies may yield multiple interacting proteins that should be verified through independent methods.

How can TRS33 antibodies be used to differentiate between TRAPP I and TRAPP II complexes?

Differentiating between TRAPP I and TRAPP II complexes is a sophisticated application of TRS33 antibodies. While TRS33 can be present in both complexes, TRAPP II contains additional specific subunits like Trs120 and Trs130 . Here's a methodological approach:

• Sucrose gradient fractionation: TRAPP I and TRAPP II sediment differently in sucrose gradients. Use TRS33 antibodies to probe fractions alongside antibodies against TRAPP II-specific subunits (Trs120, Trs130) to identify distinct complexes .

• Size exclusion chromatography: TRAPP II (~1MDa) is significantly larger than TRAPP I (~300kDa). Separate complexes by size and probe fractions with TRS33 antibodies.

• Coimmunoprecipitation followed by immunoblotting: Immunoprecipitate with TRS33 antibodies, then probe for TRAPP II-specific subunits (Trs120, Trs130) to determine complex composition .

• Immunofluorescence colocalization: TRAPP I localizes primarily to the cis-Golgi, while TRAPP II shows more trans-Golgi localization. Colocalization studies with TRS33 antibodies and organelle markers can help distinguish the complexes .

• In vitro GEF activity assays: TRAPP I activates Ypt1/Rab1, while TRAPP II activates Ypt31/32. TRS33 antibodies can immunoprecipitate complexes for subsequent GEF activity testing .

Research has shown that in trs33ts mutant cells, assembly of functional TRAPP II complex is defective, leading to reduced Ypt32 GEF activity in GST-Bet5-associated complexes . This functional assay can help distinguish between normal and impaired TRAPP complexes.

What are the best approaches for studying TRS33 interactions with other TRAPP complex components?

Studying TRS33 interactions with other TRAPP components requires sophisticated methodologies:

• Proximity labeling approaches: BioID or APEX2 fusion to TRS33 can identify proximal proteins in living cells, providing insights into transient or stable interactions.

• FRET/BRET analysis: For studying dynamics of interactions between TRS33 and other TRAPP subunits in live cells.

• Yeast two-hybrid screening: This has already revealed that TRS33 interacts with Bet3, Bet5, and Trs31, while Trs65 interacts with Bet3, Trs31, and Trs23 .

• Crosslinking mass spectrometry: Chemical crosslinking followed by mass spectrometry can identify precise interaction sites between TRS33 and partner proteins.

• Co-immunoprecipitation with sequential elution: To distinguish between direct and indirect interactions within the TRAPP complex.

• Immunofluorescence colocalization with super-resolution microscopy: For detailed spatial arrangement of TRS33 relative to other TRAPP subunits.

Research has demonstrated that TRS33 interacts genetically with both Trs120 and Trs130 and physically with Trs120, providing insight into its role in TRAPP II assembly . These interactions are functionally important, as mutations affecting them impact vesicular trafficking.

How can I use TRS33 antibodies to investigate membrane trafficking defects in disease models?

TRS33 antibodies can be valuable tools for investigating membrane trafficking defects in disease models through several approaches:

• Quantitative immunoblotting: Compare TRS33 expression levels between normal and disease models, noting that changes in TRS33 levels can affect TRAPP II assembly and function .

• Subcellular fractionation combined with immunoblotting: Determine if disease states alter the distribution of TRS33 between cytosolic and membrane fractions.

• Pulse-chase experiments: Use TRS33 antibodies to track protein transport through the secretory pathway in normal versus disease models. Research has shown that trs33ts mutant cells exhibit general secretory defects and accumulate secretory vesicles .

• Live-cell imaging with TRS33 antibody fragments: Use Fab fragments to track TRS33 dynamics in living cells.

• Correlative light and electron microscopy (CLEM): Combine TRS33 immunofluorescence with electron microscopy to detect ultrastructural changes in trafficking organelles.

• Proximity ligation assays: Detect aberrant interactions between TRS33 and other trafficking components in disease states.

Since TRS33/TRAPP complexes regulate Rab GTPases, which are master regulators of membrane trafficking, alterations in TRS33 function could have widespread effects on cellular transport processes relevant to disease pathogenesis .

Why might a TRS33 antibody work for Western blot but fail in immunofluorescence applications?

This discrepancy is common and can be explained by several factors:

• Epitope accessibility: In Western blots, proteins are denatured, exposing all epitopes. In fixed cells (immunofluorescence), the TRS33 epitope may be masked by protein-protein interactions within the TRAPP complex .

• Fixation sensitivity: Some epitopes are destroyed by certain fixatives. If using paraformaldehyde for immunofluorescence, try alternative fixation methods (methanol, acetone, or gentler crosslinkers).

• Concentration differences: TRS33 concentration may be too low for immunofluorescence detection but sufficient for Western blot where proteins are concentrated.

• Post-translational modifications: Cell-specific modifications might affect antibody recognition in intact cells but not in denatured samples.

• Antibody affinity: Western blot typically requires lower-affinity antibodies than immunofluorescence.

To troubleshoot:

• Try different fixation and permeabilization protocols

• Increase antibody concentration for immunofluorescence

• Use antigen retrieval methods

• Consider using tagged TRS33 constructs with anti-tag antibodies as alternatives

• Test the antibody on overexpressed TRS33 first to confirm it can work in principle

Studies have shown that TRS33 localizes primarily to the trans-Golgi, with weaker signals at the cis-Golgi . This specific localization pattern may be challenging to detect with antibodies that have suboptimal characteristics for immunofluorescence.

What are the optimal conditions for immunoprecipitating TRS33 and its interacting partners?

Optimizing TRS33 immunoprecipitation requires careful consideration of buffer conditions and experimental procedures:

• Lysis buffer composition:

  • Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions

  • Include protease inhibitors to prevent degradation

  • Consider phosphatase inhibitors if studying phosphorylation states

  • Maintain physiological salt concentration (150mM NaCl) to preserve interactions

• Antibody binding conditions:

  • Pre-clear lysates to reduce non-specific binding

  • Use 2-5μg antibody per mg of protein lysate

  • Allow sufficient binding time (overnight at 4°C) for maximum capture

• Washing stringency:

  • Balance between removing non-specific interactions and preserving specific ones

  • Consider a gradient of washing stringency (decreasing salt concentration)

  • Typically 3-5 washes are sufficient

• Elution method:

  • Gentle elution with excess immunizing peptide preserves interacting partners

  • Harsh elution (SDS, low pH) maximizes yield but may disrupt interactions

• Crosslinking considerations:

  • For transient interactions, consider chemical crosslinking before lysis

  • DSP (dithiobis(succinimidyl propionate)) is reversible and works well for complexes

Research has shown that TRS33 interacts with Trs120, and this interaction can be detected by co-immunoprecipitation . When planning experiments, remember that TRS33 exists in a complex with multiple other proteins, so expect to co-precipitate many interactors.

How can I distinguish between specific and non-specific signals when using TRS33 antibodies?

Distinguishing between specific and non-specific signals requires rigorous controls and validation:

• Genetic validation:

  • Test antibodies on samples from TRS33 knockout/knockdown models

  • The signal should be absent or significantly reduced in these samples

• Signal characteristics:

  • Specific signals typically show consistent molecular weight across samples

  • Non-specific signals often vary in intensity independently of TRS33 expression

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Specific signals should disappear while non-specific signals remain

• Antibody titration:

  • Specific signals typically decrease proportionally with antibody dilution

  • Non-specific signals may decrease non-linearly or persist

• Multiple antibodies approach:

  • Use antibodies targeting different epitopes of TRS33

  • Shared signals are more likely to be specific

• Correlation with protein levels:

  • Signals should correlate with TRS33 expression levels in overexpression or knockdown experiments

Research has shown that in trs33ts mutant cells, the level of Trs130 was lower than in wild-type cells, consistent with TRS33's role in TRAPP II assembly . This kind of correlation between TRS33 manipulation and expected downstream effects supports the specificity of signals detected with TRS33 antibodies.

How should variation in TRS33 subcellular localization between different cell types be interpreted?

Interpreting variations in TRS33 subcellular localization requires considering several biological and technical factors:

• Cell type-specific biology:

  • Different cell types may have distinct organizations of the secretory pathway

  • Specialized secretory cells might show enriched TRS33 in relevant compartments

  • Consider whether TRS33's role might be modulated by cell-specific factors

• Methodological considerations:

  • Ensure consistent fixation and permeabilization across cell types

  • Use identical antibody concentrations and incubation times

  • Image with consistent exposure settings

• Biological significance:

  • Changes in TRS33 localization may reflect altered TRAPP complex assembly

  • Consider whether localization correlates with cell-specific trafficking needs

  • Examine co-localization with organelle markers (Golgi, ER, endosomes)

• Quantitative analysis:

  • Measure co-localization coefficients with standard markers

  • Compare fluorescence intensity in different cellular compartments

  • Analyze the distribution pattern (punctate versus diffuse)

What approaches can be used to quantify changes in TRS33 expression levels accurately?

Accurate quantification of TRS33 expression requires careful experimental design and appropriate controls:

• Western blot quantification:

  • Use a loading control that's stable under your experimental conditions

  • Consider multiple loading controls (structural protein + metabolic enzyme)

  • Ensure signal is within linear detection range

  • Use calibration curves with recombinant TRS33 for absolute quantification

• qRT-PCR for mRNA levels:

  • Design primers specific to TRS33 (avoiding other TRAPP subunits)

  • Normalize to multiple reference genes

  • Validate PCR efficiency with standard curves

• Mass spectrometry-based approaches:

  • Targeted proteomics (SRM/MRM) for highest sensitivity and specificity

  • SILAC or TMT labeling for comparing multiple conditions

  • Include internal standard peptides for quantification

• Flow cytometry (if using fluorescent tags or for immunostaining):

  • Gate on relevant cell populations

  • Use fluorescence minus one (FMO) controls

  • Consider mean fluorescence intensity for quantification

• Immunofluorescence quantification:

  • Z-stack imaging to capture total cellular content

  • Careful background subtraction and threshold setting

  • Automated analysis of multiple fields for statistical power

When interpreting TRS33 expression data, consider that changes may affect TRAPP complex assembly and function. Research has shown that in trs33ts mutant cells, the level of Trs130 is lower than in wild-type cells, suggesting that TRS33 affects the stability or incorporation of other TRAPP II components .

How can I determine if an observed phenotype is specifically due to TRS33 dysfunction versus general TRAPP complex impairment?

Distinguishing between TRS33-specific effects and general TRAPP dysfunction requires sophisticated experimental approaches:

• Rescue experiments:

  • Reintroduce wild-type TRS33 to confirm phenotype reversal

  • Test whether overexpression of Trs65 can rescue TRS33 deficiency (functional redundancy)

  • Use structure-guided mutants affecting specific TRS33 interactions

• Comparative analysis with other TRAPP subunit deficiencies:

  • Compare phenotypes of TRS33 deficiency with those of other TRAPP components

  • Research shows that trs33ts mutants share some phenotypes with trs130ts and trs65ts mutants, including secretory defects and accumulation of secretory vesicles

• Biochemical complex analysis:

  • Use sucrose gradient fractionation or gel filtration to determine which TRAPP complexes are affected

  • Assess the integrity of remaining TRAPP complexes in the absence of TRS33

• Pathway-specific assays:

  • Test specific trafficking pathways (ER-to-Golgi, intra-Golgi, endosomal)

  • In yeast, TRS33 deficiency specifically affects Ypt31/32 GTPases and trans-Golgi trafficking

• Epistasis analysis:

  • Test whether constitutively active downstream effectors (e.g., Ypt31/32-GTP) bypass the need for TRS33

Research has shown that TRS33 and Trs65 can substitute for each other in restoring the level of TRAPP II in cells deleted for the other gene . This functional redundancy provides a valuable tool for distinguishing TRS33-specific effects from general TRAPP complex impairment.

How does TRS33 function differ between yeast and higher eukaryotes?

TRS33 exhibits fascinating functional differences across evolutionary lineages:

• Essentiality:

  • In yeast, TRS33 is nonessential but becomes essential in the absence of Trs65

  • In Arabidopsis, TRS33 (AtTrs33) is essential for apical growth and plant development

  • This suggests evolutionary divergence in the importance of TRS33

• Expression patterns:

  • Yeast TRS33 is expressed ubiquitously

  • In Arabidopsis, AtTRS33 is also ubiquitously expressed but plays a particularly critical role in apical meristems

• Functional roles:

  • In yeast, TRS33 contributes to TRAPP II assembly and function as a GEF for Ypt31/32

  • In Arabidopsis, AtTRS33 is essential for keeping apical meristematic activity and dominance, affecting auxin responses through PIN1 localization

• Redundancy mechanisms:

  • In yeast, Trs65 provides functional redundancy with TRS33

  • In plants, such redundancy appears absent, making TRS33 essential

• Complex incorporation:

  • In yeast, TRS33 is part of both TRAPP I and TRAPP II complexes

  • In mammals, the TRS33 homolog TRAPPC6A is a component of the trafficking protein particle complex

These differences highlight the evolutionary plasticity of the TRAPP complex system, with core functions being preserved while specific roles adapt to the requirements of different organisms.

What experimental systems are most appropriate for studying different aspects of TRS33 function?

Different experimental systems offer complementary advantages for studying TRS33:

For comprehensive understanding, integrating data from multiple systems is ideal. Yeast provides fundamental insights into TRAPP complex architecture and assembly , while plant systems reveal essential developmental functions . Mammalian systems bridge to human health relevance, and in vitro approaches provide mechanistic clarity.

What are the best approaches for studying post-translational modifications of TRS33?

Studying post-translational modifications (PTMs) of TRS33 requires specialized methodologies:

• Mass spectrometry-based approaches:

  • Phosphoproteomics to identify phosphorylation sites

  • Enrichment strategies for specific modifications (phospho, ubiquitin, glycosylation)

  • SILAC or TMT labeling to compare modification states between conditions

• Site-specific antibodies:

  • Generate antibodies against predicted modification sites

  • Validate specificity with non-modifiable mutants

  • Use for Western blotting or immunoprecipitation

• Mutagenesis studies:

  • Create non-modifiable mutants (e.g., S→A for phosphorylation sites)

  • Generate phosphomimetic mutants (e.g., S→D/E)

  • Test functional consequences in cellular assays

• Enzymatic assays:

  • In vitro assays with purified kinases/phosphatases

  • Deubiquitinating enzyme treatments

  • Glycosidase treatments followed by mobility shift analysis

• Live-cell imaging:

  • FRET-based sensors for specific modifications

  • Correlation with cellular events or stimuli

  • Temporal resolution of modification dynamics

While the search results don't specifically mention PTMs of TRS33, studying modifications could provide important insights into the regulation of TRAPP complex assembly and function. For example, phosphorylation could potentially regulate the interactions between TRS33 and other TRAPP subunits, influencing complex formation and activity.